ArticleThe Eurasian journal of medicine2025
Assessment of Serum Endothelial Cell-Specific Molecule-1 (ESM-1, Endocan) Levels in Patients with Diabetic Retinopathy.
Article in The Eurasian journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study aims to evaluate serum endocan (endothelial cell-specific molecule-1) levels in patients with type 2 diabetes mellitus and to determine its relationship with disease activity by comparing it with a control group.
methodsVenous blood samples were collected from 63 patients with diabetic retinopathy and healthy indi viduals who visited the policlinic between January 1, 2020, and March 1, 2020. Serum endocan and HbA1c levels were evaluated in the patients.
resultsThe mean age of the patient and control groups was 62 ± 10.19 and 60.27 ± 5.53, respectively. No statistically significant difference was observed between the patient and control groups in terms of age and gender. Serum endocan levels were found to be statistically significantly higher in the patient group with diabetic retinopathy (P < .05).
conclusionIt was hypothesized that serum endocan levels could serve as a guiding parameter in assessing the severity of diabetic retinopathy. Cite this article as: Yıldırım M, Çinici E, Çelik M, İçtaş S. Assessment of serum endothelial cell-specific molecule-1 (ESM-1, endocan) levels in patients with diabetic retinopathy. Eurasian J Med. 2025, 57(4), 1038, doi:10.5152/eurasianjmed.2025.251038.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.